Stocks and Investing
Stocks and Investing
Wed, August 24, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, August 23, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Asthika Goonewardene Maintained (STRO) at Strong Buy with Decreased Target to $21 on, Aug 23rd, 2022
Asthika Goonewardene of Truist Securities, Maintained "Sutro Biopharma, Inc." (STRO) at Strong Buy with Decreased Target from $37 to $21 on, Aug 23rd, 2022.
Asthika has made no other calls on STRO in the last 4 months.
There are 2 other peers that have a rating on STRO. Out of the 2 peers that are also analyzing STRO, 0 agree with Asthika's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Asthika
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $14 on, Monday, May 23rd, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $30 on, Wednesday, May 11th, 2022
Contributing Sources